Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.
During HHT Awareness Month, the Pulmonary Hypertension Association joins Cure HHT to raise awareness of hereditary hemorrhagic telangiectasia, a condition that can cause pulmonary hypertension. We need your help to help educate others about PH and HHT. If you have HHT-related pulmonary arterial hypertension or want to understand your risks, complete our brief survey.
Support group leaders from California and Arizona participated in the Pulmonary Hypertension Association’s most recent Support Group Leader Training Institute. The May 7 event in San Diego featured interactive activities to enhance participants’ skills in planning, promoting, hosting and managing support group meetings.
Thanks to Pulmonary Hypertension Association (PHA) advocacy efforts, the Safe Step Act moves to the full Senate floor for the first time. “This is a huge step in the legislative process. While there is more work before this bill becomes law, PHA celebrates this milestone achievement,” says PHA President and CEO Matt Granato.
Pulmonary Hypertension Association President and CEO Matt Granato recently participated in the World Heart Federation forum on rare cardiovascular diseases. Matt represented PHA and the pulmonary hypertension community at the event in Geneva, Switzerland, with Lauren Janzen, a patient and advocate from Wisconsin.
More than over 80 people attended the Pulmonary Hypertension Association’s recent education workshop. PHA Connects: PH Community Workshop addressed medication side effects, chronic thromboembolic pulmonary hypertension and blood abnormalities associated with PH, among other topics. The free, daylong event, formerly known as PHA On the Road, also included support group meetings.
The pulmonary hypertension community observed World PH Day by sharing social media posts about symptoms, related conditions and facts about PH. Additionally, the Pulmonary Hypertension Association observed World PH Day with two in-person events May 6 and will continue its global awareness efforts throughout May.
The label references trial data that shows the drug as safe and effective for moderate to high-risk PAH.
Pulmovant is enrolling participants in its Phase 3 mosliciguat study after positive Phase 2 results.
The FDA will review United Therapeutic’s new drug application for Ralinepag, a once-daily pill to treat PAH.
